Research

We investigate how diverse cancers survive by evading immune attack, dissecting the cellular, genetic, and microenvironmental mechanisms—such as altered antigen presentation, suppressive myeloid and regulatory lymphoid populations, and mutation-driven neoantigen loss—that permit immune escape. Our ultimate goal is to translate those insights into novel therapeutic strategies that reprogram the tumor microenvironment, restore effective antitumor immunity, and overcome resistance to existing treatments through targeted combination therapies, biomarker-guided patient selection, and engineered immune effectors to ultimately convert immunologically “cold” tumors into “hot” tumors responsive to durable immune control.